Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis.

MLA

Gupta, Vikas, et al. “Matching-Adjusted Indirect Comparison of the Pelabresib-Ruxolitinib Combination vs JAKi Monotherapy in Myelofibrosis.” Blood Advances, vol. 7, no. 18, Sept. 2023, pp. 5421–32. EBSCOhost, https://doi.org/10.1182/bloodadvances.2023010628.

APA

Gupta, V., Mascarenhas, J., Kremyanskaya, M., Rampal, R. K., Talpaz, M., Kiladjian, J.-J., Vannucchi, A. M., Verstovsek, S., Colak, G., Dey, D., & Harrison, C. (2023). Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis. Blood Advances, 7(18), 5421–5432. https://doi.org/10.1182/bloodadvances.2023010628

Chicago

Gupta, Vikas, John Mascarenhas, Marina Kremyanskaya, Raajit K Rampal, Moshe Talpaz, Jean-Jacques Kiladjian, Alessandro M Vannucchi, et al. 2023. “Matching-Adjusted Indirect Comparison of the Pelabresib-Ruxolitinib Combination vs JAKi Monotherapy in Myelofibrosis.” Blood Advances 7 (18): 5421–32. doi:10.1182/bloodadvances.2023010628.